Please login to the form below

Not currently logged in

Meda denies takeover report

Swedish pharmaceutical company Meda has denied a media report that Valeant has made a takeover approach for it

Sweden-based Meda has denied reports that Canada-based Valeant Pharmaceuticals International has made a takeover bid for the company.

In a statement Meda said: "Meda's board of directors has not received an approach of the kind that is described in the article. However, there are several collaborations between Meda and Valeant including joint ventures in Canada, Mexico and Australia."

A deal for Meda could be valued at more than $4bn, the Wall Street Journal reported on Tuesday.

Earlier in 2011 Valeant dropped a $5.7bn approach for Cephalon after Israel's Teva Pharmaceutical agreed to buy the US-based pharmaceutical firm for $81.50 a share, beating Valeant's $73-a-share bid.

When contacted by PMLiVE, Valeant said it declined to comment on market speculation.

Valeant recently agreed to acquire Janssen Pharmaceuticals' Ortho Dermatologics and Sanofi's Dermik.

27th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....